Kadcyla (trastuzumab emtansine)
This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Kadcyla (Ado-Trastuzumab Emtansine) injection is an antibody-drug conjugate engineered to deliver potent chemotherapy directly to HER2-positive cancer cells, potentially limiting damage to healthy tissues. It combines two anti-cancer properties joined together by a stable linker: the HER2-targeting properties of trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1.
It is indicated for HER2-positive metastatic breast cancer (MBC), and as adjuvant treatment (after primary treatment) of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease.
If a patient becomes pregnant while receiving KADCYLA, or within 7 months following the last dose of Kadcyla, please immediately report pregnancy to the local Roche Adverse Event Line at +92 301 8287010 or email at [email protected]
In case of any adverse events or safety queries, please contact: [email protected]
If you have a scientific query related to one of Roche's products, please contact: [email protected]
M-PK-00001707
Solutions
Pharma Products
:quality(90)/)